Login / Signup

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).

Carl Christoph SchimanskiStefan KasperSusanna Hegewisch-BeckerJan SchröderFriedrich OverkampFrank KullmannWolf Otto BechsteinMatthias VöhringerRobert ÖllingerFlorian LordickVolker HeinemannMichael GeißlerArmin Schulz-AbeliusHelga BernhardMichael R SchönRichard GreilPeter GalleHauke LangIrene SchmidtmannMarkus Moehler
Published in: Oncoimmunology (2020)
AE: adverse event; CP: cyclophosphamide; CRC: colorectal cancer; CT: computed tomography; ECOG: Eastern Cooperative Oncology Group; FU: follow-up; HR: hazard ratio; IHC: immunohistochemical staining; ITT: intention-to-treat; DSMB: Data Safety Monitoring Board; LLD: liver-limited disease; mCRC: metastatic colorectal cancer; MPLA: monophosphoryl lipid; AMRI: magnetic resonance imaging; MUC1: mucin 1; NA: not applicable; NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; NS: normal saline; NSCLC: non-small-cell lung carcinoma; OS: overall surviva; lPP: per protocol; RAS: Rat sarcoma; RFS: recurrence-free survival; TEAE: treatment-emergent adverse event; UICC: Union for International Cancer Control; US: ultrasound; vs.: versus.
Keyphrases